

Cátia Verpoucke is President of Relogen – Regenerative and Longevity European Council and Network, based in Belgium, is a European non-profit dedicated to advancing healthy longevity through regenerative health, sustainable innovation, smart cities, and intergenerational equity. Relogen unites experts, institutions, businesses, communities, and policymakers to create systemic solutions that improve healthspan, protect the environment, and strengthen social resilience — engaging with EU policy and funding frameworks to bridge science, policy, finance, business, and community for a sustainable future. Its focus areas include Longevity, Healthy Ageing, Smart Cities, Regenerative Health, Circular Economy, Intergenerational Equity, EU Policy, Finance & Funding, Sustainability, Wellbeing, and Advisory Networks.

She also serves as Vice President of the Belgium–Portugal Chamber of Commerce, based in Brussels, where she fosters international collaboration, innovation, and cross-border partnerships.

She is the Executive Director of Biodatapharma, a consultancy company, based in the Flemish Region of Belgium, with more than 20 years of experience supporting biotech and pharma multinationals in healthcare and life sciences, including collaborations with RNA technology platforms during the COVID-19 pandemic and projects in personalized and regenerative medicine. Biodatapharma also supports SMEs and start-ups, bridging science, business, and innovation across the health and longevity sectors.

A pioneer in Europe, at just 24 years old she founded one of the first companies in pharmacogenetics and nutrigenetics in 2004, laying the groundwork for longevity medicine by linking genetic insights with individualized prevention and nutrition. With more than two decades of International experience across Pharmaceuticals, Biotechnology, Life Sciences, MedTech, Green Biotech, AgroTech, and BIO-AI solutions, she combines scientific expertise, leadership, and fiscal strategy to drive innovation in healthspan and regenerative medicine.

She is the author of *Microbiome, Gut Health and Food Medicine* (2024), a work that resides at the intersection of cutting-edge science, preventive health, and longevity medicine. She has also supported the development of BIO-AI platforms as an investor, including the Tolufa Gut Health Platform, and is developing a longevity clinic model to translate science into practice and advance preventive and regenerative health.

Cátia is an Investor with advanced training in diplomacy, business (MBA, IE Business School, Spain), medicine, and bioengineering, with academic training at Harvard (USA), MIT (USA), ULB (Belgium), KU Leuven/VIVES (Belgium), and ULHT (Portugal).